NitroMed axes BiDil salesforce

Share this article:
NitroMed has fired the 120-member sales force behind its BiDil congestive heart failure drug for African Americans. The move comes as the company shifts its marketing focus to developing an extended release version of the drug. NitroMed CEO Jerry Karabelas said during a conference call with investors and analysts that the BiDil sales force will be replaced with a small group of “elite” marketing specialists who will target experts in heart disease. The move represents a turnaround by Nitromed, which hired 190 marketers on a contract basis to support BiDil at its July 2005 launch. When that plan proved to be ineffective, the drugmaker hired an in-house sales force. According to Karabelas, the dismissal of the sales force will save NitroMed $30 million a year in operating expenses and allow the company to devote more resources to the development of BiDil XR, a once-a-month version of the pill. The current version of the pill must be taken three times a day. NitroMed said preclinical trial results on the extended release version have been positive and said human studies are scheduled to begin in a month.
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.